Meredith Cook Sells 500 Shares of ANI Pharmaceuticals (NASDAQ:ANIP) Stock

Posted by Stanley Muller on Sep 16th, 2026

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Get Free Report) VP Meredith Cook sold 500 shares of the firm’s stock in a transaction that occurred on Monday, September 14th. The stock was sold at an average price of $70.79, for a total value of $35,395.00. Following the completion of the sale, the vice president directly owned 73,924 shares in the company, valued at approximately $5,233,079.96. This trade represents a 0.67% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Meredith Cook also recently made the following trade(s):

On Thursday, August 13th, Meredith Cook sold 500 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $75.48, for a total value of $37,740.00.
On Monday, July 13th, Meredith Cook sold 500 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $81.84, for a total value of $40,920.00.

ANI Pharmaceuticals Price Performance

Shares of NASDAQ ANIP opened at $72.11 on Wednesday. The company has a debt-to-equity ratio of 0.99, a current ratio of 2.91 and a quick ratio of 2.41. The firm has a market capitalization of $1.66 billion, a PE ratio of 15.54 and a beta of 0.45. ANI Pharmaceuticals, Inc. has a 1-year low of $69.58 and a 1-year high of $99.39. The business’s fifty day moving average price is $76.69 and its two-hundred day moving average price is $78.14.

ANI Pharmaceuticals (NASDAQ:ANIP – Get Free Report) last announced its quarterly earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.04 by $0.17. ANI Pharmaceuticals had a net margin of 11.07% and a return on equity of 27.37%. The company had revenue of $266.04 million during the quarter, compared to the consensus estimate of $260.13 million. During the same quarter in the previous year, the company posted $1.80 earnings per share. The company’s revenue for the quarter was up 25.8% compared to the same quarter last year. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. On average, research analysts expect that ANI Pharmaceuticals, Inc. will post 7.83 EPS for the current year.

Hedge Funds Weigh In On ANI Pharmaceuticals

A number of hedge funds have recently modified their holdings of the stock. Arrowstreet Capital Limited Partnership lifted its stake in ANI Pharmaceuticals by 19.3% during the first quarter. Arrowstreet Capital Limited Partnership now owns 564,360 shares of the specialty pharmaceutical company’s stock valued at $43,399,000 after buying an additional 91,153 shares in the last quarter. Dimensional Fund Advisors LP increased its position in shares of ANI Pharmaceuticals by 8.9% in the first quarter. Dimensional Fund Advisors LP now owns 531,190 shares of the specialty pharmaceutical company’s stock worth $40,843,000 after acquiring an additional 43,523 shares in the last quarter. Ranger Investment Management L.P. acquired a new stake in shares of ANI Pharmaceuticals during the second quarter valued at approximately $28,406,000. Deutsche Bank AG acquired a new stake in shares of ANI Pharmaceuticals during the second quarter valued at approximately $26,775,000. Finally, William Blair Investment Management LLC purchased a new stake in shares of ANI Pharmaceuticals in the 2nd quarter valued at approximately $21,372,000. 76.05% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

ANIP has been the topic of a number of recent analyst reports. Guggenheim cut their price target on ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating on the stock in a report on Monday, August 10th. Leerink Partners assumed coverage on ANI Pharmaceuticals in a research report on Wednesday, September 9th. They issued an “outperform” rating and a $104.00 target price on the stock. Weiss Ratings downgraded ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday, August 11th. Canaccord Genuity Group reduced their price target on ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating for the company in a research report on Monday, August 10th. Finally, Wall Street Zen cut ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 8th. Five analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $105.57.

Get Our Latest Stock Analysis on ANI Pharmaceuticals

About ANI Pharmaceuticals

(Get Free Report)

ANI Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and markets branded and generic prescription medicines. The company focuses on products with complex formulations, manufacturing requirements or specialized commercial opportunities, and serves a range of therapeutic areas.

ANI’s portfolio includes Cortrophin-Zinc, a repository corticotropin injection used for certain autoimmune and inflammatory conditions, along with a selection of branded and generic medicines.